Q-omics provides the consensus-scored BCL11A profile across patient tissues and cancer cell-line models. BCL11A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BCL11A is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, BCL11A protein abundance shows 21,094 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where BCL11A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL11A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL11A survival associations across molecular data types. BCL11A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL11A RNA expression–survival associations across cancer types. High BCL11A expression shows unfavorable associations in ACC and LIHC, but favorable associations in HNSC, UVM, PAAD and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BCL11A RNA expression.
This table summarizes BCL11A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for BCL11A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL11A shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRP, KIRC, COAD and LUSC. The KIRP box plot shows higher BCL11A RNA expression in tumor versus normal tissue (log2 FC = +0.880, t-test p < 0.001).
This table shows molecular features associated with BCL11A in patient tissues and cancer cell lines. In patient samples, BCL11A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL11A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
